70 results about "Arteriovenous malformation" patented technology

An embolic occlusion device for the treatment of aneurysms and arteriovenous malformations comprises expanded polytetrafluoroethylene (ePTFE). The ePTFE permits ingrowth of cells with connective tissue deposition to promote adherence of the aneurysm wall to the embolic device thereby preventing continued growth or re-growth of the aneurysm as well as blocking blood flow into an aneurysm. An occlusion device is also described which comprises an embolic element and a polymeric pre-formed component.

Methods and apparatus for treating or preventing endoleaks after an endovascular graft (e.g., a stent, tubular graft, stent-graft, coated stent, covered stent, intravascular flow modifier or other endovascular implant that affects, limits or prevents blood flow into a vascular defect such as an aneurysm, arterio-venous fistula, arterio-venous malformation, vessel wall perforation, etc.) has been implanted in the vasculature of a human or veterinary patient. An expansile polymeric material, such as a swellable polymer (e.g., a hydrogel), a flexible or elastomeric polymer foam (e.g. silicone, polyurethane, etc.) or a carrier member (e.g, a coil, filament, wire, etc) that carries a quantity of such expansile polymer is delivered into a perigraft space (i.e., space between the endovascular graft and the surrounding blood vessel wall) such that the polymeric material expands in situ to substantially fill the perigraft space or a portion thereof. The expansile polymeric material is delivered into he perigraft space through a catheter and/or cannula that is placed prior to, during or after the implantation of the endovascular graft. The invention includes an injector apparatus that is useable to deliver the expansile polymeric material through the wall of a previously implanted graft. After delivery into the perigraft space, the expanded polymeric material expands so as to fill all or an intended portion of the perigraft space in a manner that substantially prevents additional blood from leaking or flowing into such perigraft space. One type of blood-absorbing, porous, expansile polymeric material useable in this invention is a super-expansile hydrogel.

The present invention comprises compositions and methods for forming an endovascular occlusion to treat conditions such as aneurysms, arterio-venous malformations, excessive blood supply to tumors, massive vascular hemorrhaging, and other conditions which require an embolization to alleviate the condition. Embodiments of the present invention comprise compositions and methods that use calcium alginate, without or without endovascular coils or similar devices, to form occlusions at a site within the mammalian body targeted for occlusion.

Devices, systems, and methods used to seal a treatment area to prevent embolic agents from migrating are described. The concept has particular benefit in allowing liquid embolic to be used with a variety of intravascular therapeutic applications, including for occluding aneurysms and arteriovenous malformations in the neurovasculature.

A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (Dll4) activity to a subject in need thereof. In one embodiment, the agent is an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor. The method of the invention is useful for treating eye disorders such as ischemic retinopathy, diabetic retinopathy, age related macular degeneration, corneal neovascularization, neovascular glaucoma, or retinopathy of prematurity. The method is also useful or treating ischemic or vascular disorders such as ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension.

A system (12) is proposed for the acceleration of ions to treat Atrial Fibrillation (AF), arteriovenous malformations (AVMS) and focal epileptic lesions; this system (12) includes a pulsed ion source (1), a pre-accelerator (3) and one or more linear accelerators or linacs (5, 6, 7) operating at frequencies above 1 GHz with a repetition rate between 1 Hz and 500 Hz. The particle beam coming out of the complex (12) can vary (i) in intensity, (ii) in deposition depth and (iii) transversally with respect to the central beam direction. The possibility of adjusting in a few milliseconds and in three orthogonal directions, the location of each energy deposition in the body of the patient makes that system of accelerators (12) perfectly suited to irradiation of a beating heart.

The invention relates to a vessel plug material used in intervene treatment. Wherein, said material is temperature-sensitive nanometer gel system based on polymer N-isopropyl acrylamide (PNIPAAm), which comprises polymer N-isopropyl acrylamide nanometer gel and dispersed medium, while the gel mass percentages is 3-20% and the particle diameter of temperature-sensitive nanometer gel is 50-1000nm. The inventive temperature-sensitive nanometer gel system also can contain developer, soluble antineoplastic. The invention can control the polymer monomer kinds and ratios, the crosslinker amount and the density of temperature-sensitive nanometer gel, to control the sol-gel transformation temperature of said system, and the inventive product has better external flow property and high sol-gel transformation speed, to be used to treat vessel plug, etc.

This invention is directed to pharmaceutical compositions and methods of treating varicose veins, including telangiectasias and reticular veins, and related symptoms and diseases. Embodiments comprise injection into a varicose vein of an amphiphilic block copolymer which has properties of conversion from liquid to gel state, surfactant properties, or combinations thereof. Other embodiments consist of the combination of an amphiphilic block copolymer with a co-solvent, also allowing the injected combination to form a gel within the vein. In other embodiments, an amphiphilic block copolymer is combined with a co-solvent, a sclerosant, a vasoconstrictor, water, or combinations thereof. Other embodiments of the invention include a combination of a sclerosant such as sodium tetradecyl sulfate or polidocanol with a vasoconstrictor, preferably a long-acting vasoconstrictor such as oxymetazoline. Other embodiments are directed to compositions and methods of treating venous and arteriovenous malformations and cancer.

Devices, systems, and methods used to seal a treatment area to prevent embolic agents from migrating are described. The concept has particular benefit in allowing liquid embolic to be used with a variety of intravascular therapeutic applications, including for occluding aneurysms and arteriovenous malformations in the neurovasculature.

A method and composition for treating arteriovenous malformations (AVMs), or abnormal vasculature in the body are provided. The method comprises introducing into the region of an AVM a composition comprising a nucleophilic component, such as a thiol, and a component containing a conjugated unsaturated bond, such as an acrylate through a catheter, whereby the composition crosslinks within the body to block or occlude the AVM.

The invention relates to an implant (1) for blood vessels, in particular for influencing the blood flow in the area of arteriovenous defects, with a wall made up of individual filaments (2), which are brought together to form a substantially tubular mesh that extends in an axial direction from a proximal end to a distal end, wherein the individual filaments (2) cross one another and form intersections (3) with one another, wherein the implant (1) is deformable in such a way that, in an insertion catheter, it adopts a shape with a reduced diameter and, at the site of implantation, expands to adapt to the diameter of the blood vessel, wherein the filament ends are in each case brought together at least in pairs at the proximal and/or distal end of the mesh and are permanently interconnected, wherein the interconnected filament ends are shaped to be atraumatic,; and wherein the filaments (2) crossing one another at the intersections (3) lying distally from the filament ends are connected directly or indirectly to one another at the proximal end (10) of the implant (1). This ensures that the implant (1), after release, also expands at the proximal end as far as the vessel walls, and the filament ends do not protrude into the vessel lumen.

An occlusion device for vascular surgery, suitable for clogging treatments of vascular entry sites and for endovascular interventions such as embolizations of blood vessels, treatment of arteriovenous malformations or small aneurysms, arterial dissections and the like, by releasing in an operation region a quick setting surgical glue or haemostatic fluid, through an outlet mouth of a duct. The device prevents the surgical glue from contacting within the duct a patient's biological fluids, in particular blood, which would close the duct. In the case of clogging treatments of vascular entry sites, a backflow preventing device may be provided, preferably provided by a coupling device between the duct and an introducer sheath by which an outlet mouth is kept in contact to keep in a one-way fluid tight contact against the outer surface of the introducer sheath until an injection pressure P2 is applied to cause release of the surgical glue.

An implant for blood vessels, in particular to influence the flow of blood in the area of arteriovenous malformations. The implant has a wall comprising individual filaments combined so as to form a circular braiding, the circular braiding being positioned in elongated form and with a reduced diameter in an insertion catheter and expanding at the placement site thus adapting to the vessel diameter and increasing its braiding density.

A non-adhesive liquid-state embolizing agent for treating cerebral arteriovenous malformation (AVM) and aneurysm is composed of the water-insoluble organic polymer soluble to organic solvent containing alcohol and the medical developer.

The present invention relates to the technical field of medical devices and particularly discloses a remote-controlled liquid embolism material precise injection device. The device comprises an injection workbench and a remote switch controller, and a support frame is arranged on a surface of the injection workbench; a main switch, a power supply, a wireless signal receiver, a remote switch, a motor, a lead screw, a lead screw nut and a lead screw nut seat are arranged in a box body of the injection workbench, a workbench push rod is fixedly arranged on an upper surface of the lead screw nut seat, and the push rod extends out of a push hole; and the remote switch controller comprises a switch controller body, a battery and a wireless signal transmitter, the battery is electrically connected with the wireless signal transmitter, and the wireless signal transmitter is connected with the wireless signal receiver through a wireless signal. The remote-controlled liquid embolism material precise injection device can accurately control injection dosage of a liquid embolism material in operation processes, and reduces time of exposing medical staff to an X-ray environment when the liquid embolism material is injected in interventional operations of cerebral arteriovenous malformation, etc. by utilizing wireless control.

Disclosed are compositions for site specific delivery in the body including diseased vasculature (e.g., aneurysmal sacs, arteriovenous malformations, etc.), body lumens such as the vas deferens and fallopian tubes, cavities created in vivo for the purpose of tissue bulking, and the like. Also disclosed are methods employing such compositions as well as kits comprising such compositions.

Methods and devices are disclosed for treating a patient with an unruptured saccular aneurysm that is not associated with an arteriovenous malformation, wherein ionizing radiation is delivered to the brain of a patient through stereotactic radiosurgery. The radiosurgery may be performed with a Gamma Knife, LINAC device such as CyberKnife, or particle-beam device. The treatment impedes a natural progression of the aneurysm towards rupture and may actually obliterate the aneurysm. The treatment plan may be based in part on measured geometric properties of the aneurysm or on physical aneurysm properties such as permeability, wall thickness, wall motion, the presence of macrophages, shear stress, and flow velocities. The methods may be used in conjunction with endovascular coil embolization.

The invention discloses a detection kit for auxiliary diagnosis of cerebral arteriovenous malformation and application of the detection kit. The detection kit comprises a pair of CDKN2A gene promoter region methylation specific amplification primers and a methylation specific sequencing primer, wherein the upstream primer has a nucleotide sequence as shown in SEQ ID NO. 1; the downstream primer has a nucleotide sequence as shown in SEQ ID NO. 2; the methylation specific sequencing primer is as shown in SEQ ID NO. 3. The detection kit has the advantages that detection of cerebral arteriovenous malformation can be conveniently and quickly realized in the molecular level, the detection efficiency is high, the detection kit is highly targeted, and meanwhile, a medicine taking CDKN2A gene promoter region methylation as the target is expected to become a new measure for auxiliary diagnosis, detection and screening of cerebral arteriovenous malformation.

The invention relates to an arteriovenous malformation segmentation method and system and electronic equipment. The arteriovenous malformation segmentation method comprises the following steps: a, segmenting a blood vessel tree from a nuclear magnetic resonance angiography image to generate a blood vessel skeleton line; b, creating a spanning tree of a vascular skeleton line by using a weight-based breadth-first search algorithm, and constructing a topological path from a carotid artery root point to an AVM focus through a blood supply artery and then to a drainage vein; and c, positioning andsegmenting the AVM focus according to the spanning tree, and segmenting the blood supply artery and the drainage vein according to the topological paths of the blood supply artery and the drainage vein connected with the AVM focus. Compared with the prior art, the arteriovenous malformation segmentation method has the advantages that less human interaction is needed, and arteriovenous malformation can be automatically segmented, and AVMs with gaps and even sparse blood vessels can be well segmented, and blood supply arteries and drainage veins can be accurately segmented according to the topological relation of the blood vessels.

The invention discloses a brain arteriovenous malformation detection method and detection system based on CT images. The method comprises the steps of preprocessing the brain CT images to extract thebrain effective area; scanning the brain effective area on the basis of a three-dimensional convolution neural network algorithm, and automatically positioning all the lesion areas with brain arteriovenous malformation lesions; carrying out image segmentation on the edges of the lesion areas on the basis of the three-dimensional convolution neural network algorithm to automatically obtain lesion outline areas, and accurately distinguishing the lesions from normal brain tissue around; and automatically measuring the average density of the brain arteriovenous malformation lesions on the basis ofthe lesion outline areas. With the brain arteriovenous malformation detection method and detection system based on the CT images, the function of carrying out automatic positioning, edge automatic segmentation, average density automatic measurement and the like on the brain arteriovenous malformation lesion areas can be implemented; and furthermore, various image characteristics output when the detection is in use can be provided for doctors as the basis for determination so as to help the doctors do the clinical classification diagnosis work on the brain arteriovenous malformation lesions better.

Please insert the following Abstract on a separate sheet at the end of the application: The instant disclosure provides methods and compositions related to discovery of MAP2K (MEK1) as a therapeutic target for treatment or prevention of arteriovenous malformations (AVMs). Therapeutic and/or prophylactic uses and compositions of known MEK1 inhibitors, including small molecules and nucleic acid agents, are described.